Weight loss got these drugs to market, but the bigger opportunity, and the one population health platforms haven't caught up to, is everything else in a woman's life stage where GLP-1s intersect: PCOS, perimenopause, fertility. Join Linda Yaccarino, CEO of eMed, to discuss the true whitespace in this category, beyond the use case that made headlines.